Published in Drugs on January 01, 2004
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A (2006) 3.26
Recent sex trade and injection drug use among pregnant opiate and cocaine dependent women in treatment: The significance of psychiatric comorbidity. Addict Disord Their Treat (2010) 0.87
Characteristics of HIV-infected children recently diagnosed in Paris, France. Eur J Pediatr (2006) 0.84
Preterm premature rupture of membranes in human immunodeficiency virus-infected women: a novel case series. Infect Dis Obstet Gynecol (2006) 0.75
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA (2003) 8.76
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Fertility desires and intentions of HIV-positive women of reproductive age in Ontario, Canada: a cross-sectional study. PLoS One (2009) 1.87
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis (2004) 1.52
Canadian consensus guidelines for the care of HIV-positive pregnant women: putting recommendations into practice. CMAJ (2003) 1.25
No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. AIDS (2011) 1.22
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis (2006) 1.20
Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. AIDS (2010) 1.14
Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc (2013) 1.07
A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr (2010) 1.05
One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med (2007) 0.96
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS (2012) 0.94
Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Antivir Ther (2004) 0.92
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS (2007) 0.90
Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada. Sex Transm Dis (2009) 0.88
CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. J Infect Dis (2005) 0.85
Salvage antiretroviral therapy in HIV infection. Expert Opin Pharmacother (2002) 0.84
Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Ann Intern Med (2002) 0.83
Inclusion body myositis: another possible manifestation of antiretroviral-associated mitochondrial toxicity. AIDS (2003) 0.83
Antiretroviral therapy is not associated with reduced herpes simplex virus shedding in HIV coinfected adults: an observational cohort study. BMJ Open (2014) 0.82
Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. Pharm Res (2012) 0.81
Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV. AIDS Res Hum Retroviruses (2014) 0.80
The importance of motherhood in HIV-positive women of reproductive age in Ontario, Canada. AIDS Care (2013) 0.79
The recombinant hepatitis B surface antigen vaccine in persons with HIV: is seroconversion sufficient for long-term protection? J Infect Dis (2012) 0.79
Clinical problem-solving. Where are you from? N Engl J Med (2002) 0.78
Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection. Clin Infect Dis (2013) 0.77
Short communication: effects of age on virologic suppression and CD4 cell response in HIV-positive patients initiating combination antiretroviral therapy. AIDS Res Hum Retroviruses (2012) 0.77
Management of persons infected with human immunodeficiency virus requiring admission to the intensive care unit. Crit Care Clin (2013) 0.76
Response to Stegmann s, et Al. [J. Clin. Virol. 47 (1) (2010) 79-81]. J Clin Virol (2010) 0.75
Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen. HIV Clin Trials (2007) 0.75
In Vitro and In Situ evaluation of pH-dependence of atazanavir intestinal permeability and interactions with acid-reducing agents. Pharm Res (2014) 0.75
Raltegravir as antiretroviral therapy in HIV/AIDS. Expert Opin Pharmacother (2013) 0.75
Lipodystrophy severity does not contribute to HAART nonadherence. AIDS Behav (2006) 0.75
Field evaluation of the Merlin immediate HIV-1 and -2 test for point-of-care detection of human immunodeficiency virus antibodies. Clin Infect Dis (2002) 0.75